3F4B

Crystal structure of Plasmodium berghei Enoyl-acyl-carrier-protein reductase with TRICLOSAN


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.49 Å
  • R-Value Free: 0.254 
  • R-Value Work: 0.183 
  • R-Value Observed: 0.183 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history


Literature

The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites.

Yu, M.Kumar, T.R.Nkrumah, L.J.Coppi, A.Retzlaff, S.Li, C.D.Kelly, B.J.Moura, P.A.Lakshmanan, V.Freundlich, J.S.Valderramos, J.C.Vilcheze, C.Siedner, M.Tsai, J.H.Falkard, B.Sidhu, A.B.Purcell, L.A.Gratraud, P.Kremer, L.Waters, A.P.Schiehser, G.Jacobus, D.P.Janse, C.J.Ager, A.Jacobs, W.R.Sacchettini, J.C.Heussler, V.Sinnis, P.Fidock, D.A.

(2008) Cell Host Microbe 4: 567-578

  • DOI: https://doi.org/10.1016/j.chom.2008.11.001
  • Primary Citation of Related Structures:  
    3F4B

  • PubMed Abstract: 

    The fatty acid synthesis type II pathway has received considerable interest as a candidate therapeutic target in Plasmodium falciparum asexual blood-stage infections. This apicoplast-resident pathway, distinct from the mammalian type I process, includes FabI. Here, we report synthetic chemistry and transfection studies concluding that Plasmodium FabI is not the target of the antimalarial activity of triclosan, an inhibitor of bacterial FabI. Disruption of fabI in P. falciparum or the rodent parasite P. berghei does not impede blood-stage growth. In contrast, mosquito-derived, FabI-deficient P. berghei sporozoites are markedly less infective for mice and typically fail to complete liver-stage development in vitro. This defect is characterized by an inability to form intrahepatic merosomes that normally initiate blood-stage infections. These data illuminate key differences between liver- and blood-stage parasites in their requirements for host versus de novo synthesized fatty acids, and create new prospects for stage-specific antimalarial interventions.


  • Organizational Affiliation

    Department of Microbiology, Columbia University, New York, NY 10032, USA.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Enoyl-acyl carrier protein reductase
A, B, C, D
323Plasmodium bergheiMutation(s): 0 
Gene Names: pbfabI
EC: 1.3.1.9
UniProt
Find proteins for Q6TEI5 (Plasmodium berghei)
Explore Q6TEI5 
Go to UniProtKB:  Q6TEI5
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ6TEI5
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.49 Å
  • R-Value Free: 0.254 
  • R-Value Work: 0.183 
  • R-Value Observed: 0.183 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 64.339α = 90
b = 121.2β = 108.97
c = 87.832γ = 90
Software Package:
Software NamePurpose
HKL-2000data collection
AMoREphasing
PHENIXrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2010-03-02
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2013-06-19
    Changes: Database references
  • Version 1.3: 2023-09-06
    Changes: Data collection, Database references, Derived calculations, Refinement description